HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Koiti Inokuchi Selected Research

p 230 (p230)

6/2009Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
7/2003Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Koiti Inokuchi Research Topics

Disease

22BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
05/2023 - 08/2006
11Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2022 - 01/2016
8Multiple Myeloma
01/2021 - 07/2009
5Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
02/2023 - 09/2010
5Leukemia
01/2017 - 12/2002
4Hematologic Neoplasms (Hematological Malignancy)
01/2021 - 10/2005
4Neoplasms (Cancer)
01/2021 - 10/2005
4Disease Progression
01/2020 - 11/2008
3Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
11/2023 - 09/2011
3Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2021 - 05/2005
2Philadelphia Chromosome
11/2023 - 01/2002
2Lymphoma (Lymphomas)
02/2023 - 01/2009
2Graft vs Host Disease (Graft-Versus-Host Disease)
01/2021 - 01/2016
2Infections
01/2019 - 01/2017
2Genetic Translocation (Chromosomal Translocation)
01/2018 - 09/2011
2Pleural Effusion (Pleural Effusions)
11/2016 - 06/2006
1Residual Neoplasm
11/2023
1Cardiotoxicity
10/2022
1Histiocytic Sarcoma
08/2021
1T-Cell Lymphoma (Lymphoma, T Cell)
10/2020
1Liver Diseases (Liver Disease)
07/2020
1Hyperbilirubinemia
07/2020
1Dyskeratosis Congenita (X-Linked Dyskeratosis Congenita)
06/2020
1Leukemic Infiltration
03/2020
1Chronic Renal Insufficiency
01/2020
1Acute Kidney Injury (Acute Renal Failure)
01/2020
1Amebic Liver Abscess
01/2019
1Asymptomatic Infections
01/2019
1Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2019
1Erythema elevatum diutinum
07/2017
1Takotsubo Cardiomyopathy
01/2017
1Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
01/2017
1Exanthema (Rash)
01/2017
1Leukopenia
01/2017
1Tropical Spastic Paraparesis (Tropical Spastic Paraplegia)
01/2017
1Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
01/2017
1Cardiomyopathies (Cardiomyopathy)
01/2017
1Diabetes Mellitus
10/2016
1ST Elevation Myocardial Infarction
10/2016
1Hypertension (High Blood Pressure)
10/2016
1Polycythemia Vera
10/2016
1Thrombosis (Thrombus)
10/2016
1Dyslipidemias (Dyslipidemia)
10/2016
1Acute Coronary Syndrome
10/2016
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2016
1Respiratory Insufficiency (Respiratory Failure)
01/2016

Drug/Important Bio-Agent (IBA)

11Imatinib Mesylate (Gleevec)FDA Link
01/2018 - 08/2003
10Dasatinib (BMS 354825)FDA Link
03/2020 - 01/2012
9Tyrosine Kinase InhibitorsIBA
05/2023 - 09/2011
5Phosphotransferases (Kinase)IBA
11/2019 - 01/2014
3Proteins (Proteins, Gene)FDA Link
10/2020 - 07/2009
3LigandsIBA
01/2020 - 11/2009
3Rituximab (Mabthera)FDA Link
07/2015 - 09/2010
2CCAAT-Enhancer-Binding Protein-alphaIBA
11/2022 - 01/2016
2Signaling Lymphocytic Activation Molecule FamilyIBA
10/2020 - 10/2018
2NucleophosminIBA
10/2018 - 01/2016
2Therapeutic UsesIBA
10/2018 - 01/2018
2Core Binding Factors (Core-Binding Factor)IBA
10/2017 - 01/2017
2p 230 (p230)IBA
06/2009 - 07/2003
2Messenger RNA (mRNA)IBA
08/2003 - 01/2002
1RNA (Ribonucleic Acid)IBA
11/2023
1ranimustineIBA
02/2023
1Cytarabine (Cytosar-U)FDA LinkGeneric
02/2023
1Etoposide (VP 16)FDA LinkGeneric
02/2023
1Melphalan (Alkeran)FDA LinkGeneric
02/2023
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2022
1Muramidase (Lysozyme)IBA
08/2021
1B7-H1 AntigenIBA
01/2021
1EnzymesIBA
07/2020
1Telomerase (Telomerase Reverse Transcriptase)IBA
06/2020
1telomerase RNA (bTR)IBA
06/2020
1Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
01/2020
1Monoclonal AntibodiesIBA
01/2020
1R-CHOP protocolIBA
01/2019
1Adrenal Cortex Hormones (Corticosteroids)IBA
01/2019
1elotuzumabIBA
10/2018
1Indicators and Reagents (Reagents)IBA
10/2018
1Mucin-3IBA
10/2017
1Immunoglobulins (Immunoglobulin)IBA
10/2017
1Thalidomide (Thalomid)FDA Link
07/2017
1mogamulizumabIBA
01/2017
1amlexanox (Aphthasol)FDA Link
01/2017
1Janus Kinase 2IBA
10/2016
1HLA Antigens (Human Leukocyte Antigens)IBA
01/2016
1Bendamustine HydrochlorideFDA Link
01/2016

Therapy/Procedure

17Therapeutics
01/2021 - 05/2005
8Drug Therapy (Chemotherapy)
08/2021 - 12/2002
6Hematopoietic Stem Cell Transplantation
10/2022 - 01/2017
5Transplantation
02/2023 - 01/2009
2Induction Chemotherapy
03/2020 - 01/2002
2Drug Tapering
01/2018 - 11/2008
2Stents
01/2018 - 10/2016
1Duration of Therapy
05/2023
1Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
02/2023
1Gastrectomy
08/2021
1Stem Cell Transplantation
01/2021
1Renal Dialysis (Hemodialysis)
03/2020
1Immunotherapy
12/2019
1VAP-cyclo protocol
01/2019
1Aftercare (After-Treatment)
01/2017